CT
Celaid Therapeutics
Japan · Biotech · Healthtech
Celaid Therapeutics develops cell therapies using technology that expands blood-forming stem cells outside the body.
Expanding cells for transplantation
The company’s platform selectively expands hematopoietic stem cells, which can form blood and immune cells. Its lead candidate, CLD-001, uses frozen cord blood as starting material and is being developed for severe paediatric blood and immune disorders.
Preparing clinical development
Celaid aims to increase the usable stem-cell supply and flexibility in selecting compatible cord-blood units. The company has transferred its manufacturing process to a US development and manufacturing partner and completed a pre-IND meeting with the FDA. CLD-001 is preparing for US clinical development.
- Headquarters
- Tokyo, Japan
- Founded
- October 2020
- Lead candidate
- CLD-001
- Origins
- University of Tokyo and University of Tsukuba research
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B second close | ¥400M | Shionogi & Co — ParticipantTeikoku Ventures — Participant |